drugset / Trial / NCT01747564

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

NCT01747564

Phase 1 Completed 24 enrolled Astellas Pharma Inc
NaSingle-groupOpen-label

Summary

The purpose of this study is to evaluate safety and absorption, distribution and elimination of mirabegron after oral administration to Chinese subjects.

Timeline

Start
2012-08
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified Oral

Indications

No indication recorded.